GlycoNet researchers discovered a molecule against Methicillin-resistant (MRSA) bacteria.
Category: Press Release
Mid-year update: GlycoNet awards $885K in funding to seven projects to foster glycomics research translation
Projects seek solutions to health issues including heart disease, infections, cancer and diabetes
GlycoNet awards $500K to five research projects in Alberta
As the province’s leadership in glycomics research grows, investigators continue to work to answer important questions about human and animal health
GlycoNet researchers win $500,000 at AmorChem KNOCK OUT competition
Drs. Alexey V. Pshezhetsky and Christopher Cairo awarded half a million dollars to advance research on inhibitors to treat cardiovascular and autoimmune diseases.
$20M in government funding brings new talent in carbohydrates research to Canada and U of A
Glycomics researcher Lara Mahal announced as Canada Excellence Research Chair.
GlycoNet awards $1.45 million to eight projects aimed at improving the health of Canadians
GlycoNet awards $1.45 million to eight projects aimed at improving the health of Canadians. Funding supports glycomics translational research into post-surgical pain management, cancer diagnosis, and treatment of Parkinson’s disease, infectious diseases and chronic illness.
GlycoNet awards grants worth $90,000 to three Alberta startup companies
Glyco-based companies use funds to protect intellectual property, build business capacity EDMONTON (October 9, 2018) – The Canadian Glycomics Network (GlycoNet) awarded $90,000 in grants to three Alberta-based startup companies: 48Hour Discovery Inc., GlyCa BioSciences Inc. and PanTHERA CryoSolutions Inc. The Startup Company Funding Program recognizes the needs of start-up companies and provides financial help […]
Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery
MINNEAPOLIS, March 15, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with 48Hour Discovery (“48HD”) which grants it access to 48HD’s ligand discovery technology. This follows a license agreement with SyntArray, LLC, announced on March 13th, and […]
Extraordinary $15 million gift will create unique powerhouse initiative to fight infections
Partnership will bring together over 250 researchers under the newly created McGill Interdisciplinary Initiative in Infection and Immunity
GlycoNet, partners fund $3.5 million in health research
Grants awarded to 36 researchers across 18 institutions Canada-wide